KDM1A and acute myeloid leukemia: Two other LSD1 inhibitors, ORY-1001 and GSK2879552, have undergone clinical trials for the treatment of patients with AML (EudraCT number: 2013-002447-29; ClinicalTrials.gov identifier: NCT02177812).